1
/
of
0
Pomadex (Pomalidomide)
Pomadex (Pomalidomide)
Regular price
₱9,000.00 PHP
Regular price
Sale price
₱9,000.00 PHP
Unit price
₱300.00 each
Taxes included.
Quantity
Couldn't load pickup availability
Pomadex (Pomalidomide) – Advanced Multiple Myeloma Treatment
Pomadex is a prescription-strength antineoplastic medication containing pomalidomide, clinically proven to treat relapsed or refractory multiple myeloma in patients with prior treatment exposure. Used in combination with dexamethasone, pomalidomide targets and destroys multiple myeloma cancer cells, halting disease progression in blood cancers resistant to initial therapies such as lenalidomide and bortezomib.
Pomalidomide works by interfering with abnormal cell growth mechanisms specific to multiple myeloma, making it an effective option for patients whose conditions have worsened during or shortly after previous treatment regimens. This immunomodulatory agent is also utilized off-label for Kaposi's sarcoma management, particularly in immunocompromised patients unresponsive to conventional antiretroviral approaches.
Primary Uses and Clinical Indications
Multiple Myeloma Treatment: Pomalidomide is indicated for relapsed and refractory multiple myeloma patients with documented prior exposure to at least two standard therapies. It combines with dexamethasone to enhance therapeutic efficacy and manage disease progression within 60 days of last treatment dose.
Kaposi's Sarcoma Management: In select HIV-positive populations, pomalidomide provides an alternative when standard therapies prove inadequate.
Critical Contraindications and Safety Warnings
Pregnancy: Pomalidomide is absolutely contraindicated in pregnant patients due to documented severe teratogenic effects and birth defect risk. All female patients of childbearing potential must employ strict contraception protocols.
Breastfeeding: Lactating mothers cannot use this medication due to infant exposure risks through breast milk.
Hypersensitivity: Patients with known allergies to pomalidomide, thalidomide, or lenalidomide must avoid use.
Additional Precautions: Exercise caution in patients with thrombotic predisposition, severe hepatic or renal impairment, or active infections.
Dosage and Administration
Dosing is individualized based on clinical assessment, renal function, and physician discretion. Always follow prescribed dosage guidelines without modification.
Important Precautions
Consult your healthcare provider before initiating treatment. Do not self-medicate or alter dosing without direct medical supervision. Regular monitoring of blood counts, organ function, and clotting parameters is essential during therapy.
Pomadex is a prescription-strength antineoplastic medication containing pomalidomide, clinically proven to treat relapsed or refractory multiple myeloma in patients with prior treatment exposure. Used in combination with dexamethasone, pomalidomide targets and destroys multiple myeloma cancer cells, halting disease progression in blood cancers resistant to initial therapies such as lenalidomide and bortezomib.
Pomalidomide works by interfering with abnormal cell growth mechanisms specific to multiple myeloma, making it an effective option for patients whose conditions have worsened during or shortly after previous treatment regimens. This immunomodulatory agent is also utilized off-label for Kaposi's sarcoma management, particularly in immunocompromised patients unresponsive to conventional antiretroviral approaches.
Primary Uses and Clinical Indications
Multiple Myeloma Treatment: Pomalidomide is indicated for relapsed and refractory multiple myeloma patients with documented prior exposure to at least two standard therapies. It combines with dexamethasone to enhance therapeutic efficacy and manage disease progression within 60 days of last treatment dose.
Kaposi's Sarcoma Management: In select HIV-positive populations, pomalidomide provides an alternative when standard therapies prove inadequate.
Critical Contraindications and Safety Warnings
Pregnancy: Pomalidomide is absolutely contraindicated in pregnant patients due to documented severe teratogenic effects and birth defect risk. All female patients of childbearing potential must employ strict contraception protocols.
Breastfeeding: Lactating mothers cannot use this medication due to infant exposure risks through breast milk.
Hypersensitivity: Patients with known allergies to pomalidomide, thalidomide, or lenalidomide must avoid use.
Additional Precautions: Exercise caution in patients with thrombotic predisposition, severe hepatic or renal impairment, or active infections.
Dosage and Administration
Dosing is individualized based on clinical assessment, renal function, and physician discretion. Always follow prescribed dosage guidelines without modification.
Important Precautions
Consult your healthcare provider before initiating treatment. Do not self-medicate or alter dosing without direct medical supervision. Regular monitoring of blood counts, organ function, and clotting parameters is essential during therapy.